Nature CommunicationsNeurosciencePeer-reviewed journal article
TNF-α disrupts the malate-aspartate shuttle, driving metabolic rewiring in iPSC-derived enteric neural lineages from Parkinson's Disease patients
Bruno GhirottoiD, Luís Eduardo Gonçalves, Vivien RuderiD, Christina JamesiD, Elizaveta M. GerasimovaiD, Tania RizoiD, Holger Wend, Michaela Farrell, Juan GereziD, Natalia Cecilia Prymaczok, Merel KuijsiD, Maiia ShulmaniD, Anne HartebrodtiD, Iryna ProtsiD, Arne GessneriD, M Vieth, Friederike ZunkeiD, Jürgen WinkleriD, David B. BlumenthaliD, Fabian Joachim TheisiD, Roland RiekiD, Claudia GüntheriD, Markus NeurathiD, Pooja GuptaiD, Beate WinneriD
Abstract
Gastrointestinal (GI) dysfunction emerges years before motor symptoms in Parkinsons disease (PD), implicating the enteric nervous system (ENS) in early disease progression. However, the mechanisms linking the PD hallmark protein, -synuclein (-syn), to ENS dysfunction - and whether these mechanisms are influenced by inflammation - remains elusive. Using iPSC-derived enteric neural lineages from patients with -syn triplications, we reveal that TNF- increases mitochondrial--syn interactions, disrupts the malate-aspartate shuttle, and forces a metabolic shift toward glutamine oxidation. These alterations drive mitochondrial dysfunction, characterizing metabolic impairment under cytokine stress. Interestingly, targeting glutamate metabolism with Chicago Sky Blue 6B restores mitochondrial function, reversing TNF--driven metabolic disruption. Our findings position the ENS as a central player in PD pathogenesis, establishing a direct link between cytokines, -syn accumulation, metabolic stress and mitochondrial dysfunction. By uncovering a previously unrecognized metabolic vulnerability in the ENS, we highlight its potential as a therapeutic target for early PD intervention.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 2
- FWCI
- 4.20
- Field percentile
- top 9%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Pathological levels of α-synuclein increase basal mitophagy in Parkinson's dopamine neurons
E. D. Mock, B. Vallin, … R. Wade-Martins·bioRxiv·Nov 2, 2026
- Re-routing metabolism by the mitochondrial pyruvate carrier inhibitor MSDC-0160 attenuates neurodegeneration in a rat model of Parkinson's disease
David Mallet, Raphaël Goutaudier, … Sabrina Boulet·Molecular NeurobiologyPeer-reviewed·Jul 27, 2022
- iPSC-derived extracellular vesicles rescue deficits in human and mouse models of Parkinsons disease
Wote Amelo Rike, Utkarsh Tripathi, … Shani Stern·bioRxiv·May 26, 2026
- Alpha-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinsons disease
Fanni F. Geibl, Martin T. Henrich, … Dalton James Surmeier·Molecular NeurodegenerationPeer-reviewed·Oct 8, 2024
- Dopamine-iron homeostasis interaction rescues mitochondrial fitness in Parkinson's disease
Chiara Buoso, Markus Seifert, … Günter Weiß·Neurobiology of DiseasePeer-reviewed·Apr 21, 2024
- Type-I interferons drive the gastrointestinal inflammatory response in a mouse model of Parkinsons disease
Harrison Waters, Shuyan Chen, … Juliet Marie Taylor·Gastro Hep AdvancesPeer-reviewed·Jan 1, 2026